Skip to content

Research on the Application of Medicinal and Food Homologous Baking Products in Regulating Children's Digestive Dysfunction

Clinical Application Research on Regulating Functional Dyspepsia Syndrome in Children Based on Medicinal and Food Homologous Baking Products

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074795
Enrollment
Unknown
Registered
2023-08-16
Start date
2023-09-01
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Dyspepsia Syndrome in Children

Interventions

intervention group:medicinal and food homology baked biscuits
control group:placebo baked biscuits

Sponsors

Chengdu Women and Children's Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 3 Years

Inclusion criteria

Inclusion criteria: 1: Meeting the diagnostic criteria for decreased appetite in children with functional dyspepsia syndrome in Western medicine, with or without the other four clinical manifestations 2: (1) Clinical manifestations and diagnosis of pediatric stasis in traditional Chinese medicine 3: (2) Age range from 1 to 3 years old 4: (3) Within one month before enrollment, who had not used any other traditional Chinese medicine for dispelling accumulation, dissipating stagnation and clearing heat, as well as Prokinetic agent, antacid or antacid drugs 5: (4) The family members or primary guardians of the child agree to participate in the study and sign a written consent form 6: (5) Regularly participate in physical examination and regular follow-up at local medical institutions, and receive feeding suggestions and nutrition guidance from child care physicians, dietitian, and traditional Chinese medicine practitioners.

Exclusion criteria

Exclusion criteria: 1: (1) At the time of enrollment, there were warning symptoms of gastrointestinal diseases, such as frequent vomiting, hematemesis, apnea, growth retardation, difficulty feeding or swallowing, painful expression or abnormal posture, fever, bloody stools, changes in complexion, dehydration, difficulty in meconium excretion, etc 2: (2) Those who have severe systemic diseases such as heart, brain, liver, kidney, endocrine, and blood at the time of enrollment 3: (3) Allergic constitution and allergy to test drug 4: (4) The children with symptoms caused by intestinal stricture and rectal and colonic organic diseases (such as tumor, inflammation, anal fissure, Crohn's disease, Bowel obstruction, intestinal adhesion, colonic polyps, intestinal tuberculosis, etc.) were determined at the time of enrollment 5: (5) Disabled children (blind, deaf, mute, intellectual disabilities, mental disorders) as stipulated by law 6: (6) Participated in other clinical researchers within the past three months.

Design outcomes

Primary

MeasureTime frame
children's growth and development;Family Quality of Life Survey;

Secondary

MeasureTime frame
dietary survey;

Countries

China

Contacts

Public ContactChen Ke

Chengdu Women and Children's Central Hospital

263662086@qq.com+86 139 8178 2973

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026